Antidiabetics Market Report 2024

The antidiabetics market size has grown rapidly in recent years. It will grow from $68.32 billion in 2023 to $76.03 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The growth observed during the historical period can be attributed to several factors, the rising global prevalence of diabetes, advancements in drug development, increased awareness and diagnosis of the condition, supportive government policies, a growing elderly population, sedentary lifestyles, and rising healthcare expenditure.

The antidiabetics market size is expected to see rapid growth in the next few years. It will grow to $117.04 billion in 2028 at a compound annual growth rate (CAGR) of 11.4%. The anticipated growth during the forecast period can be linked to several factors, the rising prevalence of diabetes, growing awareness and diagnosis, increased healthcare expenditure, an expanding elderly population, and supportive government initiatives and health policies. Key trends expected in this period include the expansion of GLP-1 receptor agonists and SGLT2 inhibitors, growth in biologics and biosimilars, a focus on preventive healthcare, growth in emerging markets, and advancements in technological integration.

The antidiabetics market is anticipated to grow due to the increasing prevalence of lifestyle-related conditions. These conditions are health problems arising from behaviors such as poor diet, lack of exercise, smoking, and excessive alcohol consumption. The rise in such conditions is linked to unhealthy diets, physical inactivity, and heightened stress levels. Antidiabetic medications can manage lifestyle-related issues such as obesity and metabolic syndrome by enhancing insulin sensitivity and controlling blood sugar levels. For example, the World Health Organization reported in March 2022 that approximately 1 billion people worldwide, including 650 million adults, 340 million teenagers, and 39 million children, were obese. This figure is expected to rise, with an estimated 167 million adults and children projected to face health complications from being overweight or obese by 2025. This growing incidence of lifestyle-related conditions is driving the expansion of the antidiabetic market.

Companies in the antidiabetics sector are focusing on developing advanced treatments, such as anti-diabetic biosimilars, to improve glycemic control, reduce cardiovascular risk, and provide more effective options for diabetes management. An anti-diabetic biosimilar is a biologically similar version of an already approved diabetes drug, offering comparable safety, efficacy, and quality. For instance, in January 2024, Glenmark Pharmaceuticals Limited, based in India, introduced the first biosimilar of Liraglutide, an antidiabetic drug. This biosimilar, named Lirafit, is designed to improve glycemic control in adults with type 2 diabetes mellitus. Clinical trials have demonstrated that it reduces glycemic levels, supports weight loss, and enhances cardiovascular safety. As a GLP-1 receptor agonist, it promotes glucose-dependent insulin secretion and decreases inappropriate glucagon secretion. It is globally approved for managing type 2 diabetes in adults.

In August 2023, Lupin, an Indian pharmaceutical company, acquired the ONDERO and ONDERO MET brands from Boehringer Ingelheim International GmbH for an undisclosed amount. This acquisition is intended to strengthen Lupin's presence in the antidiabetic market and expand its product offerings. Boehringer Ingelheim International GmbH, a Germany-based company, specializes in antidiabetic medications.

Major companies operating in the antidiabetics market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen, Vertex Pharmaceuticals Incorporated, Servier Laboratories, Sun Pharmaceutical Industries Limited, Cipla Limited, Dr. Reddy's Laboratories, Lupin Limited, Torrent Pharmaceuticals Ltd, Biocon Limited, Glenmark Pharmaceuticals Ltd.

North America was the largest region in the antidiabetics market in 2023. The regions covered in the antidiabetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antidiabetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Antidiabetics are medications designed to manage diabetes mellitus, a condition marked by elevated blood glucose levels. These drugs help control blood sugar through various mechanisms, tailored to the specific type of diabetes and drug action. They work to regulate blood sugar, lessen complications, enhance health outcomes, improve metabolic control and insulin sensitivity, offer personalized treatment, and provide additional benefits such as weight management and cardiovascular protection.

The primary classes of antidiabetics include insulin, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, and others. Insulin, a hormone produced by the pancreas, is crucial for regulating blood sugar levels. Diabetes is categorized into type 1 and type 2, with antidiabetics available for pediatric, adult, and geriatric patients. Antidiabetics can be administered through various routes, such as insulin syringes or pens, insulin pumps, intravenous infusions, or oral tablets, and are distributed through multiple channels including online pharmacies, hospital pharmacies, and retail pharmacies.

The antidiabetics market research report is one of a series of new reports that provides antidiabetics market statistics, including antidiabetics industry global market size, regional shares, competitors with a antidiabetics market share, detailed antidiabetics market segments, market trends and opportunities, and any further data you may need to thrive in the antidiabetics industry. This antidiabetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antidiabetics market consists of sales of pramlintide, thiazolidinediones, insulin glargine, and exenatide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.